These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34814396)

  • 41. [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
    Hirashita T; Nakashima K; Sakai M; Sakai I
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):1123-6. PubMed ID: 17637554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High local recurrence of early-stage hepatocellular carcinoma after percutaneous thermal ablation in routine clinical practice.
    Chinnaratha MA; Sathananthan D; Pateria P; Tse E; MacQuillan G; Mosel L; Pathi R; Madigan D; Wigg AJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):349-54. PubMed ID: 25563141
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation Based on Logistic Regression Analysis.
    Ni Z; Wu B; Li M; Han X; Hao X; Zhang Y; Cheng W; Guo C
    Ultrasound Med Biol; 2022 Sep; 48(9):1733-1744. PubMed ID: 35690523
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transarterial chemoembolization versus surgery/radiofrequency ablation for recurrent hepatocellular carcinoma with or without microvascular invasion.
    Jin YJ; Lee JW; Lee OH; Chung HJ; Kim YS; Lee JI; Cho SG; Jeon YS; Lee KY; Ahn SI; Shin WY
    J Gastroenterol Hepatol; 2014 May; 29(5):1056-64. PubMed ID: 24372785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma.
    Yoo J; Lee MW; Lee DH; Lee JH; Han JK
    Liver Int; 2020 May; 40(5):1189-1200. PubMed ID: 32056353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radiofrequency ablation of hepatocellular carcinoma: Mono or multipolar?
    Cartier V; Boursier J; Lebigot J; Oberti F; Fouchard-Hubert I; Aubé C
    J Gastroenterol Hepatol; 2016 Mar; 31(3):654-60. PubMed ID: 26414644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up.
    Waki K; Aikata H; Katamura Y; Kawaoka T; Takaki S; Hiramatsu A; Takahashi S; Toyota N; Ito K; Chayama K
    J Gastroenterol Hepatol; 2010 Mar; 25(3):597-604. PubMed ID: 20074153
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term survival of hepatocellular carcinoma after percutaneous radiofrequency ablation guided by ultrasound.
    Zhang W; Luo E; Gan J; Song X; Bao Z; Zhang H; Chen M
    World J Surg Oncol; 2017 Jul; 15(1):122. PubMed ID: 28679433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [A Resected Case for Needle-Tract Implantation after Radiofrequency Ablation to the Hepatocellular Carcinoma].
    Nishio K; Kodai S; Tashima T; Kinoshita M; Hamano G; Aomatsu N; Murata A; Sakurai K; Nishii T; Tachimori A; Tamamori Y; Kubo N; Shimizu S; Maeda K; Kanazawa A
    Gan To Kagaku Ryoho; 2020 Dec; 47(13):2110-2112. PubMed ID: 33468877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatocellular carcinoma invading portal venous system in cirrhosis: long-term results of percutaneous radiofrequency ablation of both the nodule and portal vein tumor thrombus. A case control study.
    Giorgio A; Calisti G; Montesarchio L; Scognamiglio U; Matteucci P; Coppola C; Scarano F; Amendola F; Giorgio V
    Anticancer Res; 2014 Nov; 34(11):6785-90. PubMed ID: 25368292
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term results and prognostic factors in 162 patients with cirrhosis.
    Lee DH; Lee JM; Lee JY; Kim SH; Yoon JH; Kim YJ; Han JK; Choi BI
    Radiology; 2014 Mar; 270(3):900-9. PubMed ID: 24475823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C.
    Yamanaka Y; Shiraki K; Miyashita K; Inoue T; Kawakita T; Yamaguchi Y; Saitou Y; Yamamoto N; Nakano T; Nakatsuka A; Yamakado K; Takeda K
    World J Gastroenterol; 2005 Apr; 11(14):2174-8. PubMed ID: 15810088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases.
    Fukuhara T; Aikata H; Hyogo H; Honda Y; Morio K; Morio R; Hatooka M; Kobayashi T; Naeshiro N; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Chayama K
    Eur J Radiol; 2015 Aug; 84(8):1540-1545. PubMed ID: 25979193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation.
    Lencioni R; Cioni D; Crocetti L; Franchini C; Pina CD; Lera J; Bartolozzi C
    Radiology; 2005 Mar; 234(3):961-7. PubMed ID: 15665226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
    Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Negative hepatitis B envelope antigen predicts intrahepatic recurrence in hepatitis B virus-related hepatocellular carcinoma after ablation therapy.
    Chung GE; Kim W; Lee JH; Kim YJ; Yoon JH; Lee JM; Lee JY; Kim SH; Kim D; Lee HS
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1638-45. PubMed ID: 22011297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The occurrence and clinical significance of contrast agent spillover on immediate enhanced CT reexamination after radiofrequency ablation of liver cancer].
    Gao QZ; Wang ZW; Pan J; Shi HF; Zhang XB; Jin ZY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Jul; 26(7):503-507. PubMed ID: 30317772
    [No Abstract]   [Full Text] [Related]  

  • 58. Computed tomography-guided radiofrequency ablation combined with transarterial embolization assisted by a three-dimensional visualization ablation planning system for hepatocellular carcinoma in challenging locations: a preliminary study.
    Huang ZM; Zuo MX; Gu YK; Gu HF; Lai CX; Zhang TQ; Wang XC; An C; Huang JH
    Abdom Radiol (NY); 2020 Apr; 45(4):1181-1192. PubMed ID: 32006072
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiofrequency ablation vs. surgery for perivascular hepatocellular carcinoma: Propensity score analyses of long-term outcomes.
    Lee S; Kang TW; Cha DI; Song KD; Lee MW; Rhim H; Lim HK; Sinn DH; Kim JM; Kim K
    J Hepatol; 2018 Jul; 69(1):70-78. PubMed ID: 29524532
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive Factors of Treatment Outcomes After Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in the Hepatocaval Confluence: A Propensity Score Matching Analysis.
    Zhou Y; Yuan K; Yang Y; Shan X; Ji Z; Zhou D; Ouyang J; Wang Z; Zhang Q; Zhou J; Li Q
    Acad Radiol; 2023 Sep; 30 Suppl 1():S92-S103. PubMed ID: 37173236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.